MPL S505C enhances driver mutations at W515 in essential thrombocythemia
Leila N. Varghese(Ludwig Cancer Research), Stefan N. Constantinescu(Ludwig Cancer Research), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Xabier Gutiérrez-López de Ocáriz(Hospital Universitario 12 De Octubre), Gonzalo Carreño‐Tarragona, Gabriel Levy(Ludwig Cancer Research), Rosa Ayala(Hospital Universitario 12 De Octubre), Inmaculada Rapado(Wellcome Sanger Institute)
Cited by 5
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523